| DB ID | MyCo_5143 |
| Title | Diagnosis and monitoring of disseminated candidiasis based on serum/urine D/L-arabinitol ratios |
| Year | 1994 |
| PMID | 8204415 |
| Fungal Diseases involved | Disseminated candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Urine |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | D-arabitino |
| Biomarker Full Name | D-arabitino |
| Biomarker Type | Diagnostic |
| Biomolecule | Metabolite |
| Geographical Location | USA |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | In a recent book on the pathogenesis, diagnosis, and treatment of candidiasis, disseminated candidiasis is characterized as “a disease of medical progress.”l In the past four decades, the increasing use of potent cytotoxic, broad-spectrum antibi- otic or corticosteroid chemotherapy has resulted in steadily increasing morbidity and mortality due to fungal infections (mainly candidiasis and, to a lesser degree, aspergdlosis) in the severely immunocompromised patient. |
| Technique | Gas chromatography |
| Analysis Method | Metabolomics Approach |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | GC-MS |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |